Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...

SELLERSVILLE, Pennsylvania (WPVI) -- A nagging cough or congestion might not mean much to most of us. But it can be serious for those with lung conditions. Exercise testing can help specialists find ...

The FDA has expanded the approval of Jascayd (nerandomilast), an oral phosphodiesterase 4 (PDE4) inhibitor, to include treatment of progressive pulmonary fibrosis in adults.

PPF is identified by decline in lung function, worsening symptoms, and increased fibrosis on imaging, with variable criteria across studies. Risk factors for PPF include older age, male sex, smoking, ...

Dear Dr. Roach: My mother is 86 years old. She is in relatively good health. She recently saw her primary care physician for her routine checkup. Prior to her visit, she had developed cold symptoms.

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

The COVID-19 pandemic engulfed the U.S. five years ago this month, leaving not only lingering mental health effects but also long-term physical symptoms. One of those included a condition known as ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

She was diagnosed with chronic lung disease in 2018.